Asia-Pacific omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 11.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Asia-Pacific Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and rest of Asia-Pacific) Industry Trends & Forecast to 2020
Some of the major factors contributing to the growth of Asia-Pacific omega-3 ingredients for pharmaceuticals market are:
• Growing demand of functional and supplement food
• Rising burden of lifestyle diseases leads the demand of omega-3 based products
Market Players
The key market players for Asia-Pacific omega-3 ingredients for pharmaceuticals market are listed below:
• Avestia Pharma
• Novasep
• AbbVie Inc.
• KD Pharma Group
• BASF SE
• Corbion NV
• DSM
• AstraZeneca
• GlaxoSmithKline plc.
• Fresenius Kabi AG
• Croda International Plc
• ANI Pharmaceuticals, Inc.
• Epax
• Strides Pharma Science Limited
• KinOmega Biopharm Inc.
• Solutex